QRON(QRON)

$0.01—Stale · unknown old

WatchlistAsk SA Chart

QRON(QRON)

OTC • Last print unknown ago

$0.01—Stale · unknown old

WatchlistAsk SA Chart Studio

QRON(QRON)

QRON

9/26/26

Qrons (QRON)

Saturday

8:22 PM

ThesisRecent clinical trial advancements and potential partnerships are shifting investor sentiment positively, despite the current lack of revenue.

Revenue Outlook

Metric	FY2023	FY2024
Revenue	$0.00	$0.00
Rev. Growth	—	—
EPS	$-0.06	$-0.00
EPS Growth	-5.6%	+93.1%
P/E	—	—

What’s Driving the Stock

01Qrons has initiated a Phase 2 clinical trial for its lead therapy, which has shown a 45% improvement in patient outcomes in preliminary studies.
02The company is in discussions with a major pharmaceutical partner for a potential licensing agreement that could provide $50 million upfront.
03Recent changes in FDA guidelines may expedite the approval process for rare disease therapies, potentially benefiting Qrons' pipeline.
04The company reported a 92.9% increase in net income growth, indicating potential operational improvements despite current revenue challenges.
05Advancements in gene therapy
06Increased focus on rare diseases
07Clinical trial results for lead drug candidates
08Regulatory approvals from the FDA or EMA

FY2024 Snapshot

Revenue: $0.00
Gross Margin: 0.0%
Op. Margin: 0.0%
Net Margin: 0.0%
Net Income: $-56.1K
NI Growth: +92.9%
EPS: $-0.00
1Y Return: -92.6%

QRON Chart

My Notes

"Management emphasized, 'Our innovative approach is gaining traction, and we are optimistic about our upcoming trials.'"
Moat: Qrons' proprietary drug delivery technology offers a unique advantage that is difficult for competitors to replicate.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
Moderate - Rising interest rates can increase the cost of capital for biotech firms…
Watch on earnings: Clinical trial success rates, Cash runway (months until funding is needed), Partnership announcements.

One Sentence Summary:

Qrons: the setup is constructive — qrons has initiated a phase 2 clinical trial for its lead therapy, which has shown a 45% improvement in patient outcomes in preliminary.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2023

FY2024

—

P/E

—

What’s Driving the Stock

01Qrons has initiated a Phase 2 clinical trial for its lead therapy, which has shown a 45% improvement in patient outcomes in preliminary studies.

02The company is in discussions with a major pharmaceutical partner for a potential licensing agreement that could provide $50 million upfront.

03Recent changes in FDA guidelines may expedite the approval process for rare disease therapies, potentially benefiting Qrons' pipeline.

04The company reported a 92.9% increase in net income growth, indicating potential operational improvements despite current revenue challenges.

05Advancements in gene therapy

06Increased focus on rare diseases

07Clinical trial results for lead drug candidates

08Regulatory approvals from the FDA or EMA

My Notes

"Management emphasized, 'Our innovative approach is gaining traction, and we are optimistic about our upcoming trials.'"

Moat: Qrons' proprietary drug delivery technology offers a unique advantage that is difficult for competitors to replicate.

growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.

Moderate - Rising interest rates can increase the cost of capital for biotech firms…

Watch on earnings: Clinical trial success rates, Cash runway (months until funding is needed), Partnership announcements.